Cingulate to Participate in Benzinga All Live Access Event
Cingulate (NASDAQ: CING) announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST. Schaffer will discuss the company's recent European patent, the ADHD market, and potential expansion of Cingulate’s Precision Timed Release™ (PTR™) drug delivery platform into other therapeutic areas. The event can be viewed live on Benzinga's YouTube channel and later on Cingulate's website.
Cingulate (NASDAQ: CING) ha annunciato che il Presidente e CEO Shane J. Schaffer, PharmD, parteciperà a un evento dal vivo Benzinga All Access il 28 agosto 2024, alle 10:30 CST. Schaffer discuterà del recente brevetto europeo dell'azienda, del mercato dell'ADHD e della potenziale espansione della piattaforma di somministrazione farmacologica Precision Timed Release™ (PTR™) di Cingulate in altre aree terapeutiche. L'evento sarà trasmesso in diretta sul canale YouTube di Benzinga e successivamente sul sito web di Cingulate.
Cingulate (NASDAQ: CING) anunció que el presidente y CEO Shane J. Schaffer, PharmD, participará en un evento en vivo Benzinga All Access el 28 de agosto de 2024, a las 10:30 a.m. CST. Schaffer discutirá la reciente patente europea de la compañía, el mercado del TDAH y la posible expansión de la plataforma de administración de medicamentos Precision Timed Release™ (PTR™) de Cingulate a otras áreas terapéuticas. El evento se podrá ver en vivo en el canal de YouTube de Benzinga y más tarde en el sitio web de Cingulate.
Cingulate (NASDAQ: CING)는 회장 겸 CEO인 Shane J. Schaffer, PharmD가 Benzinga All Access 라이브 이벤트에 참여할 것이라고 발표했습니다. 이 행사는 2024년 8월 28일 오전 10시 30분 CST에 열릴 예정입니다. Schaffer는 회사의 최근 유럽 특허, ADHD 시장, 그리고 Cingulate의 Precision Timed Release™ (PTR™) 약물 전달 플랫폼이 다른 치료 분야로 확장할 가능성에 대해 논의할 것입니다. 이 이벤트는 Benzinga의 YouTube 채널에서 생중계되며, 나중에 Cingulate의 웹사이트에서 볼 수 있습니다.
Cingulate (NASDAQ: CING) a annoncé que le Président et CEO Shane J. Schaffer, PharmD, participera à un événement live Benzinga All Access le 28 août 2024 à 10h30 CST. Schaffer discutera du récent brevet européen de la société, du marché de l'ADHD et de l'expansion potentielle de la plateforme de délivrance de médicaments Precision Timed Release™ (PTR™) de Cingulate dans d'autres domaines thérapeutiques. L'événement sera diffusé en direct sur le canal YouTube de Benzinga et plus tard sur le site web de Cingulate.
Cingulate (NASDAQ: CING) gab bekannt, dass der Vorsitzende und CEO Shane J. Schaffer, PharmD, an einer Live-Veranstaltung Benzinga All Access am 28. August 2024 um 10:30 Uhr CST teilnehmen wird. Schaffer wird über das kürzlich erhaltene europäische Patent des Unternehmens, den ADHS-Markt und die potenzielle Erweiterung der Precision Timed Release™ (PTR™) Arzneimittelausgabeplattform von Cingulate in andere therapeutische Bereiche sprechen. Die Veranstaltung kann live auf Benzingas YouTube-Kanal und später auf Cingulates Webseite angesehen werden.
- None.
- None.
KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on August 28, 2024, at 10:30 a.m. CST.
Along with a company overview, Dr. Schaffer will discuss Cingulate’s recently issued European patent, the state of the ADHD marketplace, as well as the potential expansion of Cingulate’s PTR platform into other therapeutic areas.
The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information
visit Cingulate.com
Investor Relations
Thomas Dalton
Head of Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301
Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200
FAQ
When will Cingulate participate in the Benzinga All Access event?
Who will represent Cingulate at the Benzinga All Access event?
Where can I watch the Cingulate presentation at Benzinga All Access?
What topics will be discussed by Cingulate at the Benzinga All Access event?
What is the stock symbol for Cingulate?
